April 9, 2007 — MIV Therapeutics Inc. has announced that its recent bench test confirmed that merging Biosync Scientific's certified bare metal stent platform (which MIVT recently acquired) with its own polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro mechanical fatigue testing.
The milestone bench test further validates the recent acquisition of India-based Biosync Scientific. The acquisition is expected to accelerate the commercialization of MIVT's proprietary next generation stent technology that targets an estimated $8 billion marketplace.
The rigorous bench test combined Biosync's GenX Cr-Co, a highly competitive bare metal stent platform that has already received CE Mark certification, with MIVT's HAp technology, a novel polymer-free drug-eluting stent coating. The test results proved that MIVT's microporous ceramic coating demonstrated exceptional durability with no failures, exceeding critical FDA longevity requirements.
For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html.